309 related articles for article (PubMed ID: 29054992)
1. Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.
Rusan M; Li K; Li Y; Christensen CL; Abraham BJ; Kwiatkowski N; Buczkowski KA; Bockorny B; Chen T; Li S; Rhee K; Zhang H; Chen W; Terai H; Tavares T; Leggett AL; Li T; Wang Y; Zhang T; Kim TJ; Hong SH; Poudel-Neupane N; Silkes M; Mudianto T; Tan L; Shimamura T; Meyerson M; Bass AJ; Watanabe H; Gray NS; Young RA; Wong KK; Hammerman PS
Cancer Discov; 2018 Jan; 8(1):59-73. PubMed ID: 29054992
[TBL] [Abstract][Full Text] [Related]
2. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
[TBL] [Abstract][Full Text] [Related]
3. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y
Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587
[TBL] [Abstract][Full Text] [Related]
4. CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition.
McDermott MSJ; Sharko AC; Munie J; Kassler S; Melendez T; Lim CU; Broude EV
Cells; 2020 Mar; 9(3):. PubMed ID: 32155786
[TBL] [Abstract][Full Text] [Related]
5. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.
Lu P; Geng J; Zhang L; Wang Y; Niu N; Fang Y; Liu F; Shi J; Zhang ZG; Sun YW; Wang LW; Tang Y; Xue J
Oncogene; 2019 May; 38(20):3932-3945. PubMed ID: 30692639
[TBL] [Abstract][Full Text] [Related]
6. CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification.
Hur JY; Kim HR; Lee JY; Park S; Hwang JA; Kim WS; Yoon S; Choi CM; Rho JK; Lee JC
Cell Oncol (Dordr); 2019 Aug; 42(4):449-458. PubMed ID: 30838525
[TBL] [Abstract][Full Text] [Related]
7. CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263.
Huang T; Ding X; Xu G; Chen G; Cao Y; Peng C; Shen S; Lv Y; Wang L; Zou X
Cell Death Dis; 2019 Aug; 10(8):602. PubMed ID: 31399555
[TBL] [Abstract][Full Text] [Related]
8. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Zawistowski JS; Bevill SM; Goulet DR; Stuhlmiller TJ; Beltran AS; Olivares-Quintero JF; Singh D; Sciaky N; Parker JS; Rashid NU; Chen X; Duncan JS; Whittle MC; Angus SP; Velarde SH; Golitz BT; He X; Santos C; Darr DB; Gallagher K; Graves LM; Perou CM; Carey LA; Earp HS; Johnson GL
Cancer Discov; 2017 Mar; 7(3):302-321. PubMed ID: 28108460
[TBL] [Abstract][Full Text] [Related]
9. Nanomaterial-Facilitated Cyclin-Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction.
Huang CS; Xu QC; Dai C; Wang L; Tien YC; Li F; Su Q; Huang XT; Wu J; Zhao W; Yin XY
ACS Nano; 2021 Sep; 15(9):14744-14755. PubMed ID: 34405985
[TBL] [Abstract][Full Text] [Related]
10. CDK7 inhibitor suppresses tumor progression through blocking the cell cycle at the G2/M phase and inhibiting transcriptional activity in cervical cancer.
Zhong S; Zhang Y; Yin X; Di W
Onco Targets Ther; 2019; 12():2137-2147. PubMed ID: 30962695
[TBL] [Abstract][Full Text] [Related]
11. CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation.
Rasool RU; Natesan R; Deng Q; Aras S; Lal P; Sander Effron S; Mitchell-Velasquez E; Posimo JM; Carskadon S; Baca SC; Pomerantz MM; Siddiqui J; Schwartz LE; Lee DJ; Palanisamy N; Narla G; Den RB; Freedman ML; Brady DC; Asangani IA
Cancer Discov; 2019 Nov; 9(11):1538-1555. PubMed ID: 31466944
[TBL] [Abstract][Full Text] [Related]
12. CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer.
Yang Y; Jiang D; Zhou Z; Xiong H; Yang X; Peng G; Xia W; Wang S; Lei H; Zhao J; Qian Z; Wu S; Pang J
Cell Oncol (Dordr); 2021 Aug; 44(4):871-887. PubMed ID: 33905040
[TBL] [Abstract][Full Text] [Related]
13. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.
Sun J; Zhang Q; Sun X; Xue A; Gao X; Shen K
Cell Commun Signal; 2022 Sep; 20(1):138. PubMed ID: 36076237
[TBL] [Abstract][Full Text] [Related]
14. Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition.
East MP; Johnson GL
J Biol Chem; 2022 Feb; 298(2):101525. PubMed ID: 34958800
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines.
Ji W; Choi YJ; Kang MH; Sung KJ; Kim DH; Jung S; Choi CM; Lee JC; Rho JK
Cells; 2020 Dec; 9(12):. PubMed ID: 33287368
[TBL] [Abstract][Full Text] [Related]
16. CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway.
Chow PM; Chang YW; Kuo KL; Lin WC; Liu SH; Huang KH
Cancer Lett; 2021 Jun; 507():70-79. PubMed ID: 33741425
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological inhibition of CDK7 by THZ1 impairs tumor growth in p53-mutated HNSCC.
Ge H; Yao Y; Jiang Y; Wu X; Wang Y
Oral Dis; 2022 Apr; 28(3):611-620. PubMed ID: 33503275
[TBL] [Abstract][Full Text] [Related]
18. Elevation of effective p53 expression sensitizes wild-type p53 breast cancer cells to CDK7 inhibitor THZ1.
Wang Y; Zhang Z; Mi X; Li M; Huang D; Song T; Qi X; Yang M
Cell Commun Signal; 2022 Sep; 20(1):96. PubMed ID: 36058938
[TBL] [Abstract][Full Text] [Related]
19. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
20. Targeting CDK7 reverses tamoxifen resistance through regulating stemness in ER+ breast cancer.
Attia YM; Salama SA; Shouman SA; Ivan C; Elsayed AM; Amero P; Rodriguez-Aguayo C; Lopez-Berestein G
Pharmacol Rep; 2022 Apr; 74(2):366-378. PubMed ID: 35000145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
